[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48
1. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • After chemoradiotherapy, similar numbers of HIV+ and HIV- patients had grade III-IV toxicity.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


2. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Toppan P, Rugge M, Sinigaglia G, Nitti D, Sotti G, Monfardini S: Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Anticancer Res; 2007 Mar-Apr;27(2):1079-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
  • BACKGROUND: Rectal cancer is commonly diagnosed at a precocious stage, but for patients presenting at diagnosis with stage IV disease the best treatment is still undefined.
  • The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 40 patients with histologically proven stage IV rectal adenocarcinoma (< 12 cm from the anal verge) were examined.
  • CONCLUSION: The best treatment on diagnosis of metastatic rectal cancer is a multimodality CHT-RT approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Chen Y, Lim BK, Hashim OH: Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. J Hematol Oncol; 2009;2:37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.
  • BACKGROUND: The general enhanced expression of alpha1-antichymotrypsin (ACT), clusterin (CLU), alpha1-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported.
  • In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages of cancer.
  • RESULTS: Different altered stage correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied.
  • While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse correlation was apparently detected in the expression of LRG and CLU.
  • For patients who were diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered progression changes.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Carcinoma in Situ / blood. Ovarian Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17039-44 [15572443.001]
  • [Cites] Gene Ther. 1999 Sep;6(9):1512-9 [10490760.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1742-51 [16212428.001]
  • [Cites] Exp Oncol. 2005 Sep;27(3):233-7 [16244588.001]
  • [Cites] Proteomics. 2005 Nov;5(16):4287-95 [16254924.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):20-8 [16537992.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3938-48 [16767791.001]
  • [Cites] Neoplasma. 2007;54(1):46-50 [17203891.001]
  • [Cites] Neoplasia. 2007 Jan;9(1):1-7 [17325738.001]
  • [Cites] Front Biosci. 2007;12:2821-35 [17485262.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67 [17303479.001]
  • [Cites] Electrophoresis. 2007 Jun;28(12):1989-96 [17503403.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1845-51 [17855704.001]
  • [Cites] Proteomics. 2007 Dec;7(23):4292-302 [17963278.001]
  • [Cites] Electrophoresis. 2008 Jun;29(12):2645-50 [18494030.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(6):617-9 [19115690.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):170-6 [10646870.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):263-72 [12625785.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):27-33 [14607215.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):241-7 [15015603.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:206-10 [15247015.001]
  • [Cites] Electrophoresis. 2004 Jul;25(14):2392-401 [15274022.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Electrophoresis. 1988 Jan;9(1):28-32 [2466645.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] J Clin Lab Anal. 1995;9(2):123-8 [7536238.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Electrophoresis. 1996 Mar;17(3):612-6 [8740187.001]
  • [Cites] Kidney Int. 1998 Jun;53(6):1647-53 [9607196.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • (PMID = 19709441.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acute-Phase Proteins
  • [Other-IDs] NLM/ PMC2739531
  •  go-up   go-down


Advertisement
4. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol; 2008 Dec;5(12):737-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
  • DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936790.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


5. Wu DH, Shaffer AD, Thompson DM, Yang Z, Magnotta VA, Alam R, Suri J, Yuh WT, Mayr NA: Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume. J Magn Reson Imaging; 2008 Nov;28(5):1188-94
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume.
  • PURPOSE: To introduce, implement, and assess an iterative modification to the active deformational image segmentation method as applied to cervical cancer tumors.
  • MATERIALS AND METHODS: A comparison by Jaccard similarity (JS) between this active deformational method and manual segmentation was performed on tumors of various sizes across preradiation, 3 weeks postradiation, and 6 weeks postradiation using a General Linear Mixed Model across 121 studies from 52 patients with Stage IIB-IV cervical cancers.
  • The analysis illustrated a rate of improvement in JS with increasing tumor volume that differed between the preradiation and 6 weeks postradiation stage (P=0.0474).
  • The deformation-based segmentation method appears to demonstrate utility for delineating cervical cancer tumors, particularly in the earliest stages of radiation treatment, where agreement is greatest.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • [Cites] IEEE Trans Med Imaging. 2006 Nov;25(11):1472-82 [17117776.001]
  • [Cites] J Magn Reson Imaging. 2006 Dec;24(6):1316-25 [17058203.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5687-94 [17179104.001]
  • [Cites] Methods Inf Med. 2003;42(1):89-98 [12695800.001]
  • [Cites] Med Image Anal. 2006 Apr;10(2):215-33 [16311065.001]
  • [Cites] Stud Health Technol Inform. 1997;39:369-78 [10168933.001]
  • [Cites] J Magn Reson Imaging. 2005 Jan;21(1):1-11 [15611946.001]
  • [Cites] J Appl Clin Med Phys. 2005 Fall;6(4):106-10 [16421504.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Feb;22(2):189-99 [12715995.001]
  • (PMID = 18972365.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA071906-05; United States / NCI NIH HHS / CA / R01 CA071906; United States / NCI NIH HHS / CA / R01 CA071906-05; United States / NCI NIH HHS / CA / R01CA71906-05
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS63971; NLM/ PMC2720022
  •  go-up   go-down


6. Balogh A: [Surgical treatment of cancer at the beginning of the third millenium--based on the 2004 Krompecher Memorial Lecture of the Society of Hungarian Oncologists]. Magy Onkol; 2010 Jun;54(2):101-15
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of cancer at the beginning of the third millenium--based on the 2004 Krompecher Memorial Lecture of the Society of Hungarian Oncologists].
  • The author presents a historical overview of cancer surgery of the last century.
  • In a period of 8 years a total of 72 STCs were performed for the treatment of large bowel obstructions or symptomatic stenosis caused by cancer of the left colon.
  • STC offers: a) one stage treatment for colonic obstruction in emergency surgery, b.) removal of the tumor with sufficient oncological radicality, c.) primary reconstruction of the digestive tract, with a safe ileocolic anastomosis even in emergency cases.
  • 2.) The author reports a total of 108 middle and low third rectal cancer cases operated on by total mesorectal excision (TME) by the method of Heald.
  • The oncological basis of this procedure is the horizontal regional metastatization of rectal cancer.
  • The author succeeded in 60% of cases to perform an anterior resection with preservation of the anal sphincter, and to decrease the early (within two years after surgery) local recurrence rate from 14.5% to 6.4%, compared to the group of patients operated on by traditional technic.
  • 3.) A total of 154 patients with locally advanced - stage IV - colorectal cancer underwent extended surgery of multivisceral resections as a treatment of cancer process involving adjacent abdominal organs.
  • Surgery was performed to treat advanced cancer of the colon in 112 cases and the one of the rectum in 42 cases.
  • The mortality rate was 7% in the colon cancer group, and 12% in the group of rectal cancer patients.
  • In their tumor-free postoperative period 90% of colon cancer patients and 95% of rectal cancer patients had an improved quality of life.
  • The 5 years survival rate was 40% in the colon group and 22% in the rectal cancer group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576585.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 139
  •  go-up   go-down


7. Gilligan MA, Neuner J, Zhang X, Sparapani R, Laud PW, Nattinger AB: Relationship between number of breast cancer operations performed and 5-year survival after treatment for early-stage breast cancer. Am J Public Health; 2007 Mar;97(3):539-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between number of breast cancer operations performed and 5-year survival after treatment for early-stage breast cancer.
  • OBJECTIVES: We examined the association between number of breast cancer operations performed in a hospital (hospital volume) and all-cause and breast cancer-specific mortality using a national database and statistical methods appropriate for clustering and reducing confounding.
  • The cohort included 11225 Medicare patients who had undergone surgery for early-stage breast cancer from 1994 to 1996 in 457 different hospitals.
  • Primary outcomes were all-cause and breast cancer-specific survival rates at a mean follow-up time of 62.5 months.
  • RESULTS: In comparison with treatment in a low-volume hospital, treatment in a high-volume hospital was associated with hazard ratios of 0.83 (95% confidence interval [CI]=0.75, 0.92) for all-cause mortality and 0.80 (CI=0.66, 0.97) for breast cancer-specific mortality.
  • CONCLUSIONS: An association between the volume of breast cancer operations performed in a hospital and 5-year survival rates was observed for both all-cause and breast cancer-specific mortality.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Stat Med. 1998 Oct 15;17(19):2265-81 [9802183.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1138-44 [11948274.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1161-4 [11948278.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-26-35 [12187165.001]
  • [Cites] Ann Intern Med. 2002 Sep 17;137(6):511-20 [12230353.001]
  • [Cites] J Natl Cancer Inst. 2003 May 21;95(10):708-16 [12759388.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):606-15 [12839844.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):649-57 [14568853.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):658-65 [14568854.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1343-8 [15054452.001]
  • [Cites] Surg Gynecol Obstet. 1979 Feb;148(2):193-5 [419420.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] J Clin Epidemiol. 1994 Nov;47(11):1245-51 [7722560.001]
  • [Cites] Med Care. 1995 Apr;33(4 Suppl):AS56-66 [7723462.001]
  • [Cites] Lancet. 1995 May 20;345(8960):1265-70 [7746056.001]
  • [Cites] BMJ. 1996 Jan 20;312(7024):145-8 [8563532.001]
  • [Cites] Lifetime Data Anal. 1995;1(3):255-73 [9385105.001]
  • [Cites] Am J Public Health. 1998 Mar;88(3):454-7 [9518982.001]
  • [Cites] Am J Epidemiol. 1998 Sep 1;148(5):475-86 [9737560.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):387-98 [11297888.001]
  • (PMID = 17267725.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA081379; United States / NCI NIH HHS / CA / R01-CA81379
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1805003
  •  go-up   go-down


8. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median level of the tumor from the anal verge was 10 cm (range 3-20 cm).
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


12. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA: A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum; 2009 Aug;52(8):1375-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A twenty-year experience with adenocarcinoma of the anal canal.
  • PURPOSE: Adenocarcinoma of the anal canal is a rare malignancy with limited data regarding treatment and outcomes.
  • The purpose of this study is to evaluate disease control and survival outcomes in patients with adenocarcinoma of the anal canal.
  • METHODS: A retrospective consecutive cohort study of all patients in whom adenocarcinoma of the anal canal was diagnosed between 1983 and 2004 was performed.
  • RESULTS: Thirty-four patients were identified; six underwent palliative treatment (Stage IV, n = 4; poor performance, n = 2).
  • CONCLUSION: Combined modality treatment with radical surgical resection improves survival among patients with adenocarcinoma of the anal canal, but a high risk for distant failure emphasizes the need for effective adjuvant therapeutic regimens.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617747.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kazmi SS, Azfar M, Syed AA, Yusuf MA: Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer.
  • : e15102 Background: Preoperative chemoradiation improves local recurrence in patients with locally advanced rectal cancer<sup>1</sup>.
  • We report our experience with addition of Oxaliplatin to neoadjuvant chemoradiation for rectal cancer.
  • METHODS: For this retrospective study, thirty-six consecutive patients referred for neoadjuvant chemoradiation for rectal cancer between May 2007 and March 2008 were identified.
  • All patients had histologically proven adenocarcinoma, and were clinical stage T3/T4 or N+, except for one who was T2N0.
  • Neoadjuvant treatment consisted of upto 4 cycles of CapOx(oxaliplatin 130 mg/m2, IV, D1, capecitabine (2,000 mg/m2/day, D1-14, q3 weeks), followed by capecitabine(1650mg/m2/day) with concurrent pelvic radiation(50.4Gy/28 fractions).
  • In patients with low rectal cancer (0-5cm from anal verge), 16/26(62%) underwent resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Pinto C, Di Fabio F, Maiello E, Di Tullio P, Pini S, Aschele C, Garufi C, Bochicchio A, Pinotti G, Latiano T, Martoni A: Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study). J Clin Oncol; 2009 May 20;27(15_suppl):4110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study).
  • : 4110 Background: The aim of this phase II study is to assess the activity of preoperative external radiotherapy combined with panitumumab, oxaliplatin and 5-fluorouracil in locally advanced rectal cancer patients (pts).
  • METHODS: Pts entering the study had histologically-proven rectal adenocarcinoma, either uT3N+ or T4 N-/+ stage, with location <12 cm from the anal margin.
  • Panitumumab was administered at a dose of 6 mg/kg IV, 2 weeks before the start of chemoradiotherapy, and then in combination with chemoradiotherapy, every 2 weeks for 3 times.
  • 5-fluorouracil and oxaliplatin were administered according to an established schedule of STAR-01 Study (oxaliplatin 60 mg/m<sup>2</sup> IV weekly for six times, and 5- fluorouracil 225 mg/m<sup>2</sup>/day continuous infusion IV d 1-38).
  • The characteristics of 29 pts were: males 19 (65.5%) and females 10 (34.5%); median age 58 years (range 39-78); median Karnofsky PS 100 (range 70-100); stage: uT3N+ 22 (75.9%), uT4N- 3 (10.3%), uT4N+ 4 (13.8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961230.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Serra-Aracil X, Vallverdú H, Bombardó-Junca J, Pericay-Pijaume C, Urgellés-Bosch J, Navarro-Soto S: Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery. World J Surg; 2008 Jun;32(6):1162-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery.
  • BACKGROUND: In 1997 we launched a prospective program of transanal endoscopic microsurgery (TEM) for the treatment of rectal cancer.
  • (III) adenocarcinomas uT2- uN0, low histological grade with intention to cure; and (IV) advanced stage adenocarcinomas with palliative care RESULTS: Transanal endoscopic microsurgery was performed in 218 patients: 122 adenomas, and 96 adenocarcinomas: group II-72, group III-19, and group IV-5.
  • Nine were lost to follow-up, and so 52 patients were studied: group II-38, group III-11, and group IV-3.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Follow-Up Studies. Humans. Male. Microsurgery. Middle Aged. Prospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):402-5; discussion 405-6 [11182387.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):460-3 [15816457.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):149-51 [6825519.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):249-56 [9703594.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):77-97 [8416784.001]
  • [Cites] Gut. 1977 Dec;18(12):1045-50 [606631.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):81-3 [6697834.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Colorectal Dis. 2001 Mar;3(2):122-5 [12791005.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1170-4 [12209248.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):432-7 [15521931.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):52-7 [8287748.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18338206.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Matthiessen P, Hansson L, Sjödahl R, Rutegård J: Anastomotic-vaginal fistula (AVF) after anterior resection of the rectum for cancer--occurrence and risk factors. Colorectal Dis; 2010 Apr;12(4):351-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anastomotic-vaginal fistula (AVF) after anterior resection of the rectum for cancer--occurrence and risk factors.
  • OBJECTIVE: The aim of the study was to assess recto-vaginal fistula (RVF) after anterior resection of the rectum for cancer with regard to occurrence and risk factors.
  • METHOD: All female patients [median age 69.5 years, Union Internationale centre le Cancer (UICC) cancer stage IV in 10%] who developed a symptomatic RVF (n = 20) after anterior resection of the rectum for cancer from three separate cohorts of patients were identified and compared with those who developed conventional symptomatic leakage (n = 32), and those who did not leak (n = 338).
  • Risk factors for AVF in multivariate analysis were anastomosis < 5 cm above the anal verge (P = 0.001), preoperative radiotherapy (P = 0.004), and UICC cancer stage IV (P = 0.005).
  • CONCLUSION: Anastomotic-vaginal fistula forms a significant part of all symptomatic leakages after low anterior resection for cancer in women.
  • Risk factors for AVF included low anastomosis, preoperative radiotherapy and UICC cancer stage IV.

  • Genetic Alliance. consumer health - Vaginal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220383.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


19. Jelski W, Chrostek L, Markiewicz W, Szmitkowski M: Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer. J Clin Lab Anal; 2006;20(3):105-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer.
  • In previous experiments we found a changed level of class I ADH activity in breast cancer tissues.
  • The changed level of this enzyme in cancer cells may be reflected by the enzyme's activity in the serum.
  • Therefore, in this study we measured the activity of ADH isoenzymes and ALDH in the sera of patients with breast cancer.
  • Serum samples were taken for routine biochemical investigation from 45 women with breast cancer before treatment.
  • Among all tested classes of ADH isoenzymes, only class I had higher activity in the serum of patients with breast cancer in stage IV.
  • The total ADH and ALDH activities were not significantly higher in patients with breast cancer than in healthy controls.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16721836.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


20. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • OBJECTIVE: Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


21. Lee SE, Jeon EJ, Oh JH, Shim KH, Lee J, Kim EH, Choi SW, Min KO: [A case of advanced gastric cancer with perianal skin metastasis]. Korean J Gastroenterol; 2008 Jan;51(1):40-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with perianal skin metastasis].
  • The most common metastatic sites of gastric cancer are liver, lung, bone and adrenal gland.
  • However, skin metastases from gastric cancer are relatively rare.
  • We herein report a case of advanced gastric cancer with perianal skin metastasis in a 70-year-old male.
  • Endoscopy and abdominal CT scan demonstrated the stage IV gastric cancer.
  • We suspected that the perianal lesion was originated from gastric cancer.
  • [MeSH-minor] Aged. Anal Canal. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349561.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


22. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


23. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution of surgery for cancer of the anorectal junction].
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Chude GG, Rayate NV, Patris V, Koshariya M, Jagad R, Kawamoto J, Lygidakis NJ: Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1562-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study.
  • BACKGROUND/AIMS: Anastomotic leakage is a major problem in colorectal surgery particularly in low rectal cancer.
  • This study was designed to evaluate early morbidity, mortality and hospital stay in patients undergoing lower rectal cancer surgery concerned with or without loop ileostomy.
  • Inclusion criteria consisted of biopsy proven adenocarcinoma of the rectum located at < or = 5 cm above the anal verge, age > or = 22 years, and informed consent.
  • Exclusion criteria included age more than 90 years, associated co morbid conditions Stage IV with disease spread to liver and peritoneum.
  • RESULTS: Indications for surgery were lower rectal cancer (n=256).
  • All patients were undergoing elective surgery for lower rectal cancer.
  • So according to our study, we strongly recommend defunctioning loop ileostomy as a routine procedure in patients undergoing lower rectal cancer surgery.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102343.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  •  go-up   go-down


25. Biasco G, Nobili E, Calabrese C, Sassatelli R, Camellini L, Pantaleo MA, Bertoni G, De Vivo A, Ponz De Leon M, Poggioli G, Bedogni G, Venesio T, Varesco L, Risio M, Di Febo G, Brandi G: Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis. Dis Colon Rectum; 2006 Dec;49(12):1860-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis.
  • PURPOSE: Precancerous duodenal lesions in patients with familial adenomatous polyposis can be detected with duodenoscopy and treatment may prevent the development of cancer.
  • No duodenal cancer could be detected.
  • Eleven patients had or developed severe precancerous duodenal lesions (Stage IV) treated with endoscopic or surgical resection.
  • The distribution of patients with Stage IV according to the surgery of the colon was: 2 of 25 treated with ileoanal anastomosis and 8 of 15 with ileorectal anastomosis (P=0.0024, Fisher's exact test).
  • [MeSH-minor] Adult. Anal Canal / surgery. Anastomosis, Surgical. Duodenoscopy. Female. Follow-Up Studies. Germ-Line Mutation. Humans. Ileum / surgery. Male. Proctocolectomy, Restorative. Prospective Studies. Rectum / surgery


26. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin SR: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer; 2009;9:241
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 gene is a potential hypoxic marker in colorectal cancer patients.
  • This study investigated molecules synthesized in colorectal cancer cells during hypoxia to explore the possibility of developing molecular probes capable of detecting cell death and/or the efficiency of radiotherapy and chemotherapy.
  • METHODS: At first, we incubated two human colorectal adenocarcinoma cell lines SW480 (UICC stage II) and SW620 (UICC stage III) cells in hypoxic (< or =2% O2, 93% N2, and 5% CO2) and normoxic conditions (20% O2, 75% N2, and 5% CO2) for 24 h and 48 h.
  • Ten cancerous tissues collected from human colorectal cancer patients were examined.
  • The elevated ratio of GLUT1 was higher in stage III and IV CRC tissue specimens than in the stage I and II (2.97-4.73 versus 1.44-2.11).
  • GLUT1 mRNA was also increased in the peripheral blood of stage II and III CRC patients as compared to stage I patients, suggesting that GLUT1 may serve as a hypoxic indicator in CRC patients.
  • CONCLUSION: In conclusion, this study demonstrated that GLUT1 has the potential to be employed as a molecular marker to indicate the degree of hypoxia experienced by tumors circulating in the blood of cancer patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2008 May-Jun;33(3):270-7 [17610107.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):692-8 [18314327.001]
  • [Cites] Mol Cell Endocrinol. 2008 Sep 10;291(1-2):57-62 [18571834.001]
  • [Cites] Colorectal Dis. 2009 Mar;11(3):276-81 [18513194.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):326-41 [12469762.001]
  • [Cites] Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70 [10690586.001]
  • [Cites] J Exp Biol. 2000 Apr;203(Pt 8):1253-63 [10729275.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Cancer Lett. 2000 Jun 30;154(2):175-82 [10806305.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Prev Med. 2000 Oct;31(4):410-6 [11006067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Urology. 2002 Oct;60(4):634-9 [12385924.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):465-8 [15135470.001]
  • [Cites] J Natl Cancer Inst. 1967 Jun;38(6):839-63 [4381692.001]
  • [Cites] Cancer Res. 1972 Oct;32(10):2007-16 [4343003.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5784-8 [3016720.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Diabetes. 1988 May;37(5):657-61 [2834252.001]
  • [Cites] J Biol Chem. 1989 Nov 15;264(32):18884-9 [2553725.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14523-6 [1634504.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Stem Cells. 1996 Jan;14(1):10-5 [8820945.001]
  • [Cites] NMR Biomed. 1996 Aug;9(5):185-94 [9067999.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1103-13 [9097992.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):149-62 [9436976.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):68-72 [10098401.001]
  • [Cites] Oncologia. 1956;9(2):75-83 [13335077.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8554-60 [15623639.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):126-32 [15699632.001]
  • [Cites] Cancer Lett. 2005 Nov 8;229(1):115-22 [16157223.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Mar;70(2):45-55 [16456867.001]
  • [Cites] Int J Mol Med. 2006 May;17(5):737-47 [16596255.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):279-88 [16289546.001]
  • [Cites] Int J Radiat Biol. 2006 Oct;82(10):699-757 [17118889.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):265-70 [17497098.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75 [17707270.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12):955-60 [18211986.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):348-52 [17962202.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):697-700 [18246802.001]
  • [Cites] Adv Exp Med Biol. 2008;614:127-36 [18290322.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):603-8 [18191183.001]
  • [Cites] BMC Cancer. 2008;8:194 [18616803.001]
  • (PMID = 19619276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  • [Other-IDs] NLM/ PMC3087329
  •  go-up   go-down


27. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG: Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol; 2005 Oct 13;3:68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance.
  • This study examined PlGF expression at protein and message levels in non-small cell lung cancer (NSCLC), in which no reports on the significance of PlGF expression is available to date.
  • RESULTS: PlGF was positively stained mainly in cytoplasm of lung cancer cells.
  • Real time PCR analysis revealed that PlGF mRNA was higher in the cancer tissue than normal tissue (0.95 +/- 0.19 vs. 0.57 +/- 0.24; p < 0.005) and that PlGF mRNA was significant higher in III-IV stage patients than in I-II stage patients (1.03 +/- 0.20 vs. 0.80 +/- 0.17; p = 0.011).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Jan;14(1):161-8 [9863024.001]
  • [Cites] J Biol Chem. 1994 Oct 14;269(41):25646-54 [7929268.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7717-23 [7706320.001]
  • [Cites] Oncogene. 1993 Apr;8(4):925-31 [7681160.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):62-6 [7596435.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1628-36 [15951164.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):1-6 [15192305.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):591-7 [15166262.001]
  • [Cites] Adv Cancer Res. 1995;67:281-316 [8571818.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3154-62 [8621715.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):493-8 [9207183.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1069-77 [12454810.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):771-5 [10023341.001]
  • [Cites] Nat Med. 2001 May;7(5):575-83 [11329059.001]
  • (PMID = 16223445.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1276823
  •  go-up   go-down


28. O'Neil BH, Tepper JE: Current options for the management of rectal cancer. Curr Treat Options Oncol; 2007 Oct;8(5):331-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current options for the management of rectal cancer.
  • Patients diagnosed with rectal cancer should undergo locoregional staging with transrectal endoscopic ultrasound (EUS) or surface coil array MRI of the pelvis if that technique is available.
  • Patients thought to have more than very early stage (T1 or T2) disease should undergo abdominal imaging as well by CT or MRI, and chest imaging with either CXR or preferably CT.
  • The care of rectal cancer patients should be coordinated amongst an experienced multidisciplinary team to maximize the chance of cure and to minimize both local recurrence and complications of therapy.
  • For patients with very early stage disease (T1N0 or T2N0), local resection with or without chemoradiation may be adequate therapy, but these patients must be selected carefully and should be without any poor prognostic factors.
  • For the majority of patients with T3N0 or greater rectal cancer, standard therapy consists of neoadjuvant continuous 5-FU and radiation followed by surgery and further chemotherapy (either with 5-FU, capecitabine, or FOLFOX).
  • Select patients with high (>10 cm from the anal verge) uT3N0 tumors may be at sufficiently low risk of local recurrence to justify omission of radiotherapy.
  • Patients with stage IV rectal cancer may still require local therapy with radiation, surgery, or both; however, care should be taken in these patients that chemotherapy is not excessively delayed as this is the one modality in this case that can result in improved survival.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181024.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K23 CA 118431-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 51
  •  go-up   go-down


29. Akasu T, Takawa M, Yamamoto S, Ishiguro S, Yamaguchi T, Fujita S, Moriya Y, Nakanishi Y: Intersphincteric resection for very low rectal adenocarcinoma: univariate and multivariate analyses of risk factors for recurrence. Ann Surg Oncol; 2008 Oct;15(10):2668-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred twenty consecutive patients with T1-T3 rectal cancers located 1-5 (median 3) cm from the anal verge underwent ISR.
  • RESULTS: Fifty patients had disease categorized as stage I, 21 as stage II, 46 as stage III, and 3 as stage IV on the basis of International Union Against Cancer tumor, node, metastasis staging system.
  • Univariate analysis of the risk factors for local recurrence revealed pathologic T, pathologic stage, focal dedifferentiation, microscopic resection margins, and preoperative serum CA 19-9 level to be statistically significant.
  • Univariate analysis of the risk factors for distant recurrence indicated tumor location, combined resection, tumor annularity, pathologic N, lateral pelvic lymph node metastasis, pathologic stage, histologic grade, lymphovascular invasion, perineural invasion, and adjuvant chemotherapy to be significant.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Neoplasm Recurrence, Local / diagnosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618181.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


30. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


31. Yoo JH, Hasegawa H, Ishii Y, Nishibori H, Watanabe M, Kitajima M: Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer. Colorectal Dis; 2005 Sep;7(5):434-40
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer.
  • With direct coloanal anastomosis for cases of lower rectal cancer in which the distal surgical margin is difficult to secure by the double stapling technique.
  • Of these, two patients (one stage 0 and one stage IV) were excluded from the analysis of oncological outcome.
  • There was an association between distant metastasis and TNM or pT stage.
  • The overall survival rates for stage I, II and III were 85%, 80% and 89%, respectively.
  • CONCLUSION: The surgical indications of this operation should be limited to patients with T1 rectal cancer or tumours less than 3 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Fecal Incontinence / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proctocolectomy, Restorative. Rectum / surgery. Surveys and Questionnaires. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108877.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS: Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol; 2005 Dec;99(3):608-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
  • OBJECTIVES: Studies from the colorectal literature have shown that factors associated with anastomotic leak after colorectal resection include long surgical time (>2 h), multiple blood transfusions, and short distance to the anal verge.
  • The aim of this study was to assess the morbidity associated with en bloc resection of ovarian carcinoma with low anterior resection and anastomosis in patients undergoing primary cytoreductive surgery for advanced disease.
  • METHODS: We performed a retrospective chart review of all patients who had undergone primary cytoreduction for advanced epithelial ovarian cancer with rectosigmoid resection followed by low rectal anastomosis between January 1994 and June 2004.
  • There were 52 stage IIIC (74%) and 18 stage IV (26%) cancers.
  • CONCLUSIONS: In women undergoing primary cytoreductive surgery, the morbidity associated with en bloc resection of ovarian carcinoma with low rectosigmoid resection and anastomosis without protective ileostomy was acceptably low, with an anastomotic leak rate of less than 2%.


33. Chamlou R, Parc Y, Simon T, Bennis M, Dehni N, Parc R, Tiret E: Long-term results of intersphincteric resection for low rectal cancer. Ann Surg; 2007 Dec;246(6):916-21; discussion 921-2
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • INTRODUCTION: In the treatment of very low rectal cancer, a distal resection margin of more than 1 cm can be obtained by partial internal sphincteric resection, allowing a sphincter preserving surgery.
  • Thus, intersphincteric resection (ISR) has been proposed as an alternative to abdominoperineal resection for selected low rectal cancer.
  • Cancer-related survival and locoregional recurrence rates were calculated using the Kaplan-Meier method.
  • RESULTS: Ninety patients (59 males, 31 females) with a tumor at a median distance of 35 mm (range, 22-52) from the anal verge had an ISR.
  • Thirteen patients (14.4%) died of cancer recurrence.
  • In univariate analysis, overall survival was significantly influenced by pTNM stage and T stage (pT 1-2 vs. 3-4: P = 0.008 and stage I-II vs. III-IV: P = 0.03).
  • After adjustment for age, gender, tumor level, and pTNM stage, preoperative radiotherapy was the only factor associated with a risk of fecal incontinence [OR (IC 95%) = 3.1 (1.0-9.0), P = 0.04].
  • [MeSH-major] Adenocarcinoma / epidemiology. Anal Canal / surgery. Colectomy / methods. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043092.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Tanaka K, Noura S, Ohue M, Seki Y, Gotou K, Motoori M, Kishi K, Takachi K, Eguchi H, Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O, Imaoka S, Murata K, Kameyama M: [A case of refractory inguinal lymphorrhea cured by lipiodol lymphangiography]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2162-4
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 80-year-old female who underwent an abdomino-perineal resection with lateral pelvic lymph node dissection and inguinal lymph node extraction for anal canal cancer.
  • Histologically, the tumor was a poorly differentiated adenocarcinoma and considered to be stage IV (a2, n3 (+), P0, H3, M (-), cur C) in the Japanese classification of colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219932.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


35. Baek WS, Kubba SV: Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary. Gynecol Oncol; 2008 Dec;111(3):544-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 66-year-old female with stage IV ovarian papillary serous cystadenocarcinoma presented with perianal numbness and sphincter dysfunction.
  • On exam she had decreased anal tone with saddle anesthesia.
  • CONCLUSION: Ovarian cancer metastasizng to the cauda equina should be highly suspected based on the clinical presentation alone, even with unremarkable imaging studies.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Meningeal Carcinomatosis / pathology. Ovarian Neoplasms / pathology. Polyradiculopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433846.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Williams DK, Muddiman DC: Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J Proteome Res; 2009 Feb;8(2):1085-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry.
  • A method employing protein cleavage isotope dilution mass spectrometry (PC-IDMS) was developed for quantification of C-reactive protein (CRP) in human plasma.
  • The comparison of these results generated an R(2) = 0.9708 which indicates successful quantification of CRP from human plasma utilizing the methodology described herein.
  • In addition, data is shown that illustrates that, as epithelial ovarian cancer (EOC) progresses from stage I to stage IV, mean levels of CRP increase.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):992-4 [12766009.001]
  • [Cites] Proteomics. 2003 Apr;3(4):422-32 [12687610.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1253-6; discussion R1257-8 [14557241.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1175-86 [15048997.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):235-44 [15113099.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):644-52 [15253448.001]
  • [Cites] Anal Biochem. 1974 May;59(1):277-82 [4407487.001]
  • [Cites] Clin Chem. 1996 Oct;42(10):1676-82 [8855153.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12513-22 [9139702.001]
  • [Cites] Clin Chem. 1998 Jan;44(1):52-60 [9550558.001]
  • [Cites] Clin Chem. 1999 Feb;45(2):206-12 [9931042.001]
  • [Cites] J Physiol. 2005 Feb 15;563(Pt 1):23-60 [15611012.001]
  • [Cites] Methods. 2005 Mar;35(3):265-73 [15722223.001]
  • [Cites] Am Heart J. 2005 Jun;149(6):971-6 [15976777.001]
  • [Cites] J Lab Clin Med. 2005 Jun;145(6):305-8 [15976758.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2005 Jan;2(1):29-36; quiz 58 [16265340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17442-7 [16293687.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):573-88 [16332733.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1682-7 [16823976.001]
  • [Cites] J Proteome Res. 2006 Dec;5(12):3318-25 [17137333.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):673-8 [17317883.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Clin Chem. 2001 Mar;47(3):403-11 [11238289.001]
  • [Cites] Scand J Clin Lab Invest. 2001 May;61(3):227-35 [11386609.001]
  • [Cites] Clin Chem. 2002 Feb;48(2):269-77 [11805007.001]
  • [Cites] Clin Chem Lab Med. 2002 Jan;40(1):78-89 [11916276.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):363-9 [12551853.001]
  • [Cites] Anal Chem. 2003 Feb 1;75(3):445-51 [12585469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6940-5 [12771378.001]
  • (PMID = 19196186.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA105295-04; United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295-04
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS86745; NLM/ PMC2637469
  •  go-up   go-down


37. Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpé S, De Meester I: Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem; 2009 Jun;57(6):531-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DPP8 was localized in spermatozoids in an earlier stage of maturation.
  • [MeSH-minor] Animals. Cattle. Dipeptidyl Peptidase 4 / metabolism. Dipeptidyl-Peptidase IV Inhibitors. Epididymis / enzymology. Immunoblotting. Immunohistochemistry. Indoles / pharmacology. Isoleucine / analogs & derivatives. Isoleucine / pharmacology. Male. Organ Specificity. Piperidines / pharmacology. Pyrazines / pharmacology. Rats. Sitagliptin Phosphate. Species Specificity. Spermatozoa / enzymology. Testis / enzymology. Triazoles / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SITAGLIPTIN .
  • Hazardous Substances Data Bank. L-Isoleucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Anat. 1974 Jun;140(2):167-79 [4826242.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Jul 15;18(14):4154-8 [18556199.001]
  • [Cites] Int J Androl. 1986 Dec;9(6):435-52 [3570534.001]
  • [Cites] Andrologia. 1990;22 Suppl 1:10-24 [2132063.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1992 Jun;30(6):333-8 [1380841.001]
  • [Cites] J Immunol Methods. 1996 Jan 16;189(1):99-105 [8576585.001]
  • [Cites] J Urol. 1998 Nov;160(5):1905-9 [9783983.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Mar;45(2):225-31 [10230732.001]
  • [Cites] J Med Chem. 2005 Jan 13;48(1):141-51 [15634008.001]
  • [Cites] Biochem J. 2005 Mar 1;386(Pt 2):315-24 [15487984.001]
  • [Cites] Diabetes. 2005 Oct;54(10):2988-94 [16186403.001]
  • [Cites] Adv Exp Med Biol. 2006;575:109-16 [16700514.001]
  • [Cites] Peptides. 2007 Feb;28(2):257-68 [17223229.001]
  • [Cites] Curr Top Med Chem. 2007;7(6):621-35 [17352682.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1736-41 [17363526.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):31-49 [17328877.001]
  • [Cites] J Leukoc Biol. 2007 May;81(5):1252-7 [17287297.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):785-92 [17786309.001]
  • [Cites] Front Biosci. 2008;13:2319-26 [17981714.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6140-50 [11012666.001]
  • [Cites] J Histochem Cytochem. 2001 Dec;49(12):1473-86 [11724895.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):185-93 [12459266.001]
  • [Cites] Eur J Cell Biol. 2003 Feb;82(2):53-73 [12647932.001]
  • [Cites] Biochem J. 2003 Jul 1;373(Pt 1):179-89 [12662155.001]
  • [Cites] Crit Rev Clin Lab Sci. 2003 Jun;40(3):209-94 [12892317.001]
  • [Cites] Curr Opin Chem Biol. 2003 Aug;7(4):496-504 [12941425.001]
  • [Cites] Protein Expr Purif. 2004 May;35(1):142-6 [15039077.001]
  • [Cites] J Med Chem. 2004 May 20;47(11):2906-16 [15139769.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 13;1679(1):18-28 [15245913.001]
  • [Cites] J Reprod Fertil. 1973 Jan;32(1):33-44 [4700805.001]
  • [Cites] J Reprod Fertil. 1973 Jan;32(1):45-53 [4144778.001]
  • [Cites] Front Biosci. 2008;13:2364-75 [17981718.001]
  • [Cites] Front Biosci. 2008;13:3168-80 [17981786.001]
  • [Cites] J Med Chem. 2007 Nov 15;50(23):5568-70 [17958345.001]
  • [Cites] Reproduction. 2007 Dec;134(6):721-9 [18042629.001]
  • [Cites] J Histochem Cytochem. 2008 Feb;56(2):147-55 [17967935.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):855-66 [17943180.001]
  • [Cites] Front Biosci. 2008;13:3558-68 [18508455.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Jul 15;18(14):4159-62 [18556198.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • (PMID = 19188489.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptidyl-Peptidase IV Inhibitors; 0 / Indoles; 0 / Piperidines; 0 / Pyrazines; 0 / Triazoles; 0 / UAMC00039; 0 / UAMC00132; 04Y7590D77 / Isoleucine; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.- / Dpp8 protein, rat; EC 3.4.14.- / Dpp9 protein, rat; EC 3.4.14.5 / Dipeptidyl Peptidase 4; TS63EW8X6F / Sitagliptin Phosphate
  • [Other-IDs] NLM/ PMC2690406
  •  go-up   go-down


38. Kim SH, Park IJ, Joh YG, Hahn KY: Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients. Surg Endosc; 2006 Aug;20(8):1197-202
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients.
  • BACKGROUND: This study aimed to prospectively evaluate operative safety and mid-term oncologic outcomes of laparoscopic rectal cancer resection performed by a single surgeon.
  • 257 patients (82.4%) had tumors located below 12 cm from the anal verge.
  • Distribution of TNM stages was 0:I:II:III:IV = 4.2%:17.9%:32.4%:37.2%:8.3%.
  • With a mean follow-up of 30 months in the stage I-III patients, the local recurrence rate was 2.9%.
  • CONCLUSION: Laparoscopic resection of rectal cancer provided safe operative parameters and adequate mid-term oncologic outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):403-5 [15932567.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):428-33 [15800782.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Surg Gynecol Obstet. 1984 Jan;158(1):33-8 [6691164.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):230-4 [15609379.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 16865622.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood; 2010 Aug 12;116(6):886-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):195-200 [11275369.001]
  • [Cites] Blood. 2010 Aug 19;116(7):1083-91 [20442367.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):1199-210 [11407314.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):541-8 [12689658.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Leukemia. 2004 Mar;18(3):385-93 [14737075.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):644-7 [5768862.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):103-8 [6765955.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):588-91 [6937239.001]
  • [Cites] Annu Rev Biochem. 1981;50:845-77 [6267992.001]
  • [Cites] Br J Haematol. 1981 Sep;49(1):23-8 [6974004.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:191-9 [3094325.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Biochemistry. 1998 Jun 16;37(24):8615-21 [9628722.001]
  • [Cites] Immunopharmacology. 1998 Jul;40(1):1-9 [9776473.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1268-78 [18279955.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1563-75 [19541822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8 [11287638.001]
  • (PMID = 20427701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00289549
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA81534; United States / PHS HHS / / P30-16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.1.3.2 / Phosphoric Monoester Hydrolases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2924226
  •  go-up   go-down


40. Rivera R, Barboglio PG, Hellinger M, Gousse AE: Staging rectourinary fistulas to guide surgical treatment. J Urol; 2007 Feb;177(2):586-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etiology was rectal injury during open radical prostatectomy in 5 patients, laparoscopic prostatectomy in 1, radiation induced fistula for prostate cancer treatment (brachytherapy and external beam radiation therapy) in 2, neoadjuvant external beam radiation therapy in 2, ischial decubitus ulcer in 3 with spinal cord injury, and cryotherapy and external beam radiation therapy in 1.
  • Cases were staged as stage I--low (less than 4 cm from anal verge and nonirradiated), stage II--high (more than 4 cm from anal verge and nonirradiated), stage III--small (less than 2 cm irradiated fistula), stage IV--large (more than 2 cm irradiated fistula) and stage V--large (ischial decubitus fistula).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222638.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Itoh H, Iwasaki M, Hanaoka T, Sasaki H, Tanaka T, Tsugane S: Urinary bisphenol-A concentration in infertile Japanese women and its association with endometriosis: A cross-sectional study. Environ Health Prev Med; 2007 Nov;12(6):258-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median urinary BPA concentration in women with stage 0-1 endometriosis (0.74 μg/g creatinine) did not significantly differ from that in those with stage II-IV endometriosis (0.93 μg/g creatinine) (p for difference=0.24).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Shokuhin Eiseigaku Zasshi. 2001 Apr;42(2):71-8 [11486386.001]
  • [Cites] Environ Mol Mutagen. 2006 Oct;47(8):571-8 [16795089.001]
  • [Cites] Chem Res Toxicol. 2002 Oct;15(10):1281-7 [12387626.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):365-70 [12401363.001]
  • [Cites] Environ Health Perspect. 2003 Jan;111(1):101-4 [12515686.001]
  • [Cites] Obstet Gynecol Clin North Am. 2003 Mar;30(1):1-19, vii [12699255.001]
  • [Cites] Environ Health Perspect. 2004 Mar;112(3):331-8 [14998749.001]
  • [Cites] Nihon Eiseigaku Zasshi. 2004 Nov;59(4):403-8 [15626028.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Environ Res. 2005 Sep;99(1):118-25 [15927178.001]
  • [Cites] Sci Total Environ. 2006 Apr 15;359(1-3):90-100 [16546516.001]
  • [Cites] Environ Sci. 2006;13(1):15-29 [16685249.001]
  • [Cites] Nihon Koshu Eisei Zasshi. 1991 Aug;38(8):567-74 [1747547.001]
  • [Cites] Fertil Steril. 1985 Mar;43(3):351-2 [3979573.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 12;312(2):441-8 [14637157.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):177-200 [15157637.001]
  • [Cites] Fertil Steril. 2004 Dec;82(6):1501-8 [15589850.001]
  • [Cites] Shokuhin Eiseigaku Zasshi. 2004 Dec;45(6):339-43 [15794093.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):49-57 [15866492.001]
  • [Cites] Int J Hyg Environ Health. 2005;208(4):237-45 [16078637.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5407-13 [16097788.001]
  • [Cites] Anal Bioanal Chem. 2005 Oct;383(4):638-44 [16132150.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:11-22; discussion 34-6, 396-406 [11949940.001]
  • (PMID = 21432072.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2723486
  • [Keywords] NOTNLM ; HPLC-MS/MS / endocrine disruptor / epidemiology / urine / xenoestrogen
  •  go-up   go-down


42. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
Hazardous Substances Data Bank. L-Ascorbic Acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients received As(2)O(3) 0.25 mg/kg iv and AA 1000 mg iv for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2-6.
  • The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


43. Ferrigno R, Novaes PE, Silva ML, Nishimoto IN, Nakagawa WT, Rossi BM, Ferreira Fde O, Lopes A: Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol; 2006;1:5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the retrospective analysis of patients with locally advanced rectal cancer treated with neodjuvant radiochemotherapy.
  • In 71 patients (70.3%) the primary tumor was located up to 6 cm from the anal verge and in 30 (29.7%) from 6.5 cm to 10 cm.
  • Age, gender, tumor fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local control (LC) at five years.
  • Patients with tumors more than 6 cm above the anal verge had better LC (93% Vs 69%; p = 0.04).
  • The postoperative TNM stage was a significant factor for DFS (I:64.1%, II:69.6%, III:35.2%, IV:11.1%; p < 0.001) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; p = 0.005).

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Radiother. 2004 Oct;8(5):297-304 [15561595.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1798-807 [15622571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77 [15708244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1129-35 [15752893.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8 [10705009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):713-8 [10837955.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56 [11020583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80 [11072165.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):727-31 [11129419.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1779-86 [11251009.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):311-8 [11352304.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):659-63 [11395233.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):176-83 [11516868.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):801-6 [11776494.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):493-8 [11923604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74 [12062610.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):568-73 [12095973.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):192-202 [12576893.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):298-304 [12626903.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):448-53 [12682535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9 [12909219.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1189-93 [12972962.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1194-9 [12972963.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):261-4 [14648784.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):265-70 [14648785.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):219-24 [14728936.001]
  • [Cites] Tumori. 2004 May-Jun;90(3):303-9 [15315310.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1323-30 [15484346.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1218-24 [1634912.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3486-92 [8490898.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):169-75 [8083110.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Cancer Invest. 1995;13(1):96-107 [7834479.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1473-5 [7635791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6):611-24 [8539636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):419-20 [8876881.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11):1701-8, 1713-4; discussion 1714-18 [8953589.001]
  • [Cites] Lancet. 1996 Dec 14;348(9042):1605-10 [8961989.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Radiographics. 1997 May-Jun;17(3):609-26 [9153700.001]
  • [Cites] Radiology. 1997 Aug;204(2):533-8 [9240549.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74 [9486606.001]
  • [Cites] Ann Surg Oncol. 1998 Mar;5(2):113-8 [9527263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1067-75 [9539561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):493-7 [10203081.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • (PMID = 16722598.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1459184
  • [General-notes] NLM/ Original DateCompleted: 20060619
  •  go-up   go-down


44. Taweevisit M, Wisadeopas N, Phumsuk U, Thorner PS: Increased mast cell density in haemorrhoid venous blood vessels suggests a role in pathogenesis. Singapore Med J; 2008 Dec;49(12):977-9
MedlinePlus Health Information. consumer health - Hemorrhoids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Haemorrhoids are an abnormal, tortuous dilatation of the arteriovenous plexus of the anus.
  • METHODS: 48 cases of haemorrhoids were retrospectively collected at King Chulalongkorn Memorial Hospital, with normal anorectal tissue from surgically-removed colorectal cancer serving as controls.
  • Similar values were found for haemorrhoids showing chronic changes and those in a more acute stage.
  • [MeSH-major] Anal Canal / blood supply. Hemorrhoids / pathology. Hemorrhoids / physiopathology. Mast Cells / pathology. Veins / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122946.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


45. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun; 2009 Jun 05;9:5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had no evidence of disease; 10 (53%) had stage III disease, 3 each (16%) had stage IIB and IV disease, 2 (11%) had choroidal and 1 (5%) had anal mucosal involvement.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2003 Sep;10(20):1754-65 [12939642.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4 [6933476.001]
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] J Invest Dermatol. 1988 Apr;90(4):459-66 [3280698.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3961-8 [7706734.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 [8610135.001]
  • [Cites] Science. 1996 Jul 19;273(5273):352-4 [8662521.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4749-57 [8840994.001]
  • [Cites] J Immunother. 1997 Jan;20(1):15-25 [9101410.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):350-63 [18200635.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6867-75 [10586088.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • (PMID = 19496531.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01CA33049; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCCIH NIH HHS / AT / P50AT002779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide
  • [Other-IDs] NLM/ NIHMS201057; NLM/ PMC2888533
  •  go-up   go-down


46. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL: Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res; 2009 Nov 15;15(22):7029-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Ninety-seven patients with resected melanoma (stage II-IV) were enrolled, stratified by stage, and randomized to receive a cellular melanoma vaccine with or without GM-CSF.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1996 Jul-Aug;46(4):225-44 [8673695.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):291-7 [10344219.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):720-31 [15613691.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3015-24 [16116189.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):237-45 [16047143.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):215-22 [17200357.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):226-32 [17116643.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]
  • [Cites] Eur J Haematol. 2007 Oct;79(4):292-6 [17655695.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):49-59 [18446337.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3239-46 [10866317.001]
  • [Cites] Am J Nephrol. 2000 Jan-Feb;20(1):53-6 [10644869.001]
  • [Cites] J Immunother. 2000 Mar-Apr;23(2):275-81 [10746554.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4169-80 [12377960.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4549-54 [12454111.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):186-200 [12491520.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):367-73 [12843799.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2447-56 [12855617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):64-72 [14593498.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Immunol. 1988 Dec 1;141(11):3882-8 [3141506.001]
  • [Cites] Cancer Immunol Immunother. 1989;29(4):247-54 [2752392.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1131-45 [2001448.001]
  • [Cites] Blood. 1991 Aug 1;78(3):609-15 [1830497.001]
  • [Cites] J Clin Lab Anal. 1992;6(5):329-36 [1403355.001]
  • [Cites] Ann Surg. 1992 Oct;216(4):463-82 [1417196.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):512-22 [8460920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2913-20 [9738558.001]
  • (PMID = 19903777.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA012582; United States / NCI NIH HHS / CA / R01 CA076489-05; United States / NCI NIH HHS / CA / CA12582; United States / NCI NIH HHS / CA / CA87071; United States / NCI NIH HHS / CA / CA076489-05; United States / NCI NIH HHS / CA / P01 CA012582-35; United States / NCI NIH HHS / CA / K08 CA087071; United States / NCI NIH HHS / CA / CA76489; United States / NCI NIH HHS / CA / R01 CA076489
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS219270; NLM/ PMC2920049
  •  go-up   go-down


47. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


48. Yeh JJ, Weiser MR, Shia J, Hwu WJ: Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol; 2005 Jun;6(6):438-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of stage IV anal mucosal melanoma to chemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925823.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement